Continuing evolution of opioid use in primary care practice: implications of emerging technologies

被引:1
作者
Stanos, Steven [1 ,2 ]
机构
[1] Rehabil Inst Chicago, Ctr Pain Management, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL USA
关键词
Analgesics; Drug abuse; Opioid formulations; Opioids; Primary care; Substance abuse; CHRONIC NONCANCER PAIN; ABUSE-DETERRENT FORMULATIONS; PRESCRIPTION DRUG DIVERSION; CHRONIC NONMALIGNANT PAIN; NONMEDICAL USE; PENTAZOCINE-NALOXONE; CLINICAL GUIDELINES; FAMILY PHYSICIANS; AMERICAN ACADEMY; PERSISTENT PAIN;
D O I
10.1185/03007995.2012.722988
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary care physicians, nurse practitioners, and nurses are often the first to evaluate patients with pain and many patients depend on these clinicians for pain relief. The growing evidence supporting use of opioids for appropriately selected patients means that primary care practitioners must be knowledgeable regarding ever-evolving pain-management strategies. Scope: This review summarizes core considerations in opioid prescribing in the primary care setting, the risks of undertreatment of pain, the challenges and barriers associated with prescribing opioids, identifying risk factors that may predict problematic use, and emerging formulation technologies expected to assist clinicians in better achieving effective pain control while minimizing risks for misuse or diversion. Results: Primary care physicians face considerable challenges in optimizing pain management while minimizing potential for misuse, abuse and diversion. Opioid treatment decisions are based not only on the type of pain but also the patient's psychosocial history, including a screening for predicting aberrant behaviors and, in some patients, substance abuse. New opioid formulations are available to assist clinicians in achieving adequate patient relief while reducing risk of tampering and abuse. Primary care practitioners need to be aware of these new options and integrate them into clinical treatment decisions. Conclusions: The strategic use of new opioid formulations and better patient assessment may lead to more successful use of opioids in the management of pain, while limiting or lowering the risk of the development of an addiction problem, abuse or diversion.
引用
收藏
页码:1505 / 1516
页数:12
相关论文
共 98 条
  • [1] Acura Pharmaceuticals Inc. Aversion Technology, AV TECHN
  • [2] [Anonymous], 2011, ELI216 EL PHARM INC
  • [3] [Anonymous], 2010, STAT PURD PHARM LP R
  • [4] [Anonymous], 2009, FDA APPR EMB MAN MOD
  • [5] [Anonymous], 2010, PURD PHARM LP REC FD
  • [6] [Anonymous], 2010, INT ANN SIGN ADV ITS
  • [7] [Anonymous], 2005, COUNT DIV AB CONTR P
  • [8] [Anonymous], 2012, EMBEDA PACK INS
  • [9] [Anonymous], GUID IND AS IN PRESS
  • [10] [Anonymous], 2010, FDA APPR EXALGO HYDR